Drug release characteristics of different mesalazine products using USP apparatus 3 to simulate passage through the GI tract

Dissolution Technologies

Volumn 9, Issue 4, 2002, Pages 6-12

  Klein, Sandra ^a   Rudolph, Markus W ^a   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYL CELLULOSE; EUDRAGIT; MESALAZINE;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIGESTIVE TRACT PARAMETERS; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GRANULE; DRUG RELEASE; DRUG RELEASE TESTING; DRUG SOLUBILITY; ENTERIC COATED TABLET; GASTROINTESTINAL TRANSIT; INFLAMMATORY BOWEL DISEASE; PH; SIMULATION; ULCERATIVE COLITIS; UNITED STATES PHARMACOPOEIA APPARATUS 3;

EID: 84962120892     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT090402P6     Document Type: Article

References (7)

1. Rohrs BR et al. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations. J Pharm Sci, 1995 Aug;84(8):922-6
2. Bondesen S., Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic. Studies in relation to inflammatory bowel disease ­ preface, Pharmacol. Toxicol. 81 (Suppl. 2) (1997) 5-28[1]
3. Klein S. et al. Comparing drug release characteristics of different marketed Mesalazine dosage forms by simulating their gi-passage with a new BIO-DIS method (Abstract), Proceedings 28th International Symposium on Controlled Release and Bioactive Materials, #6089, Controlled Release Society, Inc., San Diego, California, USA, 2001
4. Davis SS et al. A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm, 1984, 21:167-177
5. Davis SS et al. Transit of pharmaceutical dosage forms through the small intestine, Gut 1986 Aug;27(8):886-92
6. Coupe AJ et al. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects, Pharm Res 1991 Mar;8(3):360-4
7. Rudolph MW et al. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001: 183-190